Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL2782100 | 0.93 | CHRM4 (0.42) | MTNR1AMTNR1BHSD11B1CHRM4HTR4 | |
| SCHEMBL4699899 | 0.89 | MTNR1A (0.44) | MTNR1AMTNR1BHSD11B1HTR4DRD2 | |
| SCHEMBL2782154 | 0.89 | HSD11B1 (0.58) | HSD11B1CHRM4HTR1AHTR7 | |
| SCHEMBL2780254 | 0.89 | OPRM1 (0.49) | HSD11B1CHRM4SLC6A4 | |
| SCHEMBL2778462 | 0.89 | CHRM4 (0.57) | HSD11B1CHRM4 | |
| SCHEMBL2780443 | 0.88 | MTNR1A (0.49) | MTNR1AMTNR1BHSD11B1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL2782544 | 0.87 | MTNR1A (0.49) | MTNR1AMTNR1BHSD11B1DRD2DRD3 | |
| SCHEMBL2780700 | 0.84 | HSD11B1 (0.59) | HSD11B1CHRM4 | |
| Citric Acid SCHEMBL4701377 | 0.83 | DRD2 (0.40) | MTNR1AMTNR1BHSD11B1HTR4DRD2 | |
| SCHEMBL2781043 | 0.83 | HTR1A (0.50) | DRD2DRD3HTR1ASLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560823-B1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2008-07-09 | — | — | EP | claimed |
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2005-12-15 | — | — | US | claimed |
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | OPRL1, OPRM1, OGFRL1 | MTNR1A 253/4885MTNR1B 304/4885HSD11B1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.